



## **Bictegravir**

Catalog No: tcsc0014685

Available Sizes
Size: 1mg
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 1611493-60-7
Formula: C <sub>21</sub> H <sub>18</sub> F <sub>3</sub> N <sub>3</sub> O <sub>5</sub>
Pathway: Metabolic Enzyme/Protease;Anti-infection
Target: HIV Integrase;HIV
Purity / Grade: >98%
Solubility: DMSO: 83.3 mg/mL (185.37 mM; Need ultrasonic and warming)
Alternative Names: GS-9883





## **Observed Molecular Weight:**

449.38

## **Product Description**

Bictegravir is a novel, potent inhibitor of **HIV-1 integrase** with an  $IC_{50}$  of 7.5 nM.

IC50 & Target: IC50: 7.5 nM (HIV-1 integrase)[1]

In Vitro: Bictegravir (BIC) inhibits the strand transfer activity with an IC $_{50}$  of 7.5± 0.3 nM. Relative to its inhibition of strand transfer activity, Bictegravir is a much weaker inhibitor of 3′-processing activity of HIV-1 IN, with an IC $_{50}$  of 241±51 nM. Bictegravir enhances the accumulation of 2-LTR circles ~5-fold relative to the mock-treated control and reduces the amount of authentic integration products in infected cells by 100-fold. Bictegravir potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC $_{50}$ s of 1.5 and 2.4 nM, respectively. Bictegravir exhibits potent antiviral effects in both primary CD4<sup>+</sup> T lymphocytes and monocyte-derived macrophages, with EC $_{50}$ s of 1.5±0.3 nM and 6.6±4.1 nM, respectively, which are comparable to values obtained in T-cell lines<sup>[1]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!